Evolution of the thrombolytic treatment window for acute ischemic stroke

Current Neurology and Neuroscience Reports

Volumn 10, Issue 1, 2010, Pages 29-33

  Stemer, Andrew ^a   Lyden, Patrick ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ECASS III; Intravenous rt PA; Ischemic stroke; Time window

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PLACEBO;

BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EARLY INTERVENTION; FIBRINOLYTIC THERAPY; HUMAN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77649149669     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0076-8     Document Type: Review

References (28)

1. T Thom N Haase W Rosamond, et al. 2006 Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 113 e85 e151 10.1161/CIRCULATIONAHA.105.171600 16407573 (Pubitemid 43754289)
2. D Lloyd-Jones R Adams M Carnethon, et al. 2009 Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 480 486 10.1161/CIRCULATIONAHA.108.191259 19171871
3. CL Ogden MD Carroll LR Curtin, et al. 2006 Prevalence of overweight and obesity in the United States, 1999-2004 JAMA 295 1549 1555 10.1001/jama.295.13. 1549 1:CAS:528:DC%2BD28Xjt12itrk%3D 16595758
4. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group. N Engl J Med 1996, 335:145.
5. JA Zivin M Fisher U DeGirolami, et al. 1985 Tissue plasminogen activator reduces neurological damage after cerebral embolism Science 230 1289 10.1126/science.3934754 1:CAS:528:DyaL28XksFGitw%3D%3D 3934754
6. PD Lyden JA Zivin WA Clark, et al. 1989 Tissue plasminogen activator mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits Neurology 39 703 1:CAS:528:DyaL1MXktFOns7g%3D 2496332
7. Lyden PD: Thrombolytic Therapy for Acute Stroke. Totowa, NJ: Humana Press; 2005.
8. JA Sattin SE Olson L Liu, et al. 2006 An expedited code stroke protocol is feasible and safe Stroke 37 2935 2939 10.1161/01.STR.0000249057.44420.4b 17095736 (Pubitemid 44900812)
9. JC Grotta WS Burgin A El-Mitwalli, et al. 2001 Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000 Arch Neurol 58 2009 2013 10.1001/archneur.58.12.2009 1:STN:280: DC%2BD38%2FivVyrsQ%3D%3D 11735774
10. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333:1581.
11. Hacke W, Kaste M, Fieschi C, et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017-1025.
12. T Steiner E Bluhmki M Kaste, et al. 1998 The ECASS 3-hour cohort Cerebrovasc Dis 8 198 10.1159/000015851 1:STN:280:DyaK1czkvVKrsQ%3D%3D 9684058 (Pubitemid 28342442)
13. W Hacke M Kaste C Fieschi, et al. 1998 Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 1245 10.1016/S0140-6736(98)08020-9 1:CAS:528:DyaK1cXnt1egtLo%3D 9788453 (Pubitemid 28470336)
14. EC Haley Jr C Lewandowski BC Tilley 1997 Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight Ann Emerg Med 30 676 10.1016/S0196-0644(97)99996-0 9360581
15. Lyden PD, Lyden PD: Thrombolytic Therapy for Stroke. Totowa, NJ: Humana Press; 2001.
16. JL Saver 2007 Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm Stroke 38 2279 2283 10.1161/STROKEAHA.107.487009 1:CAS:528:DC%2BD2sXotVansb8%3D 17641238 (Pubitemid 47457569)
17. Hoffman JR, Schriger DL: A graphic reanalysis of the NINDS trial. Ann Emerg Med 2009, 54:329-336, 336.e321-336.e335.
18. PA Barber J Zhang A Demchuk, et al. 1015 Why are stroke patients excluded from TPA therapy? Neurology 2001 56
19. EE Smith AR Abdullah I Petkovska, et al. 2005 Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke Stroke 36 2497 2499 10.1161/01.STR.0000185798.78817.f3 1:CAS:528:DC%2BD2MXhtFaksb7F 16210552 (Pubitemid 41566987)
20. JA Zivin 2009 Acute stroke therapy with tissue plasminogen activator (TPA) since it was approved by the U.S. Food and Drug Administration (FDA) Ann Neurol 66 6 10 10.1002/ana.21750 19681102
21. MJ Alberts 1998 TPA in acute ischemic stroke: United States experience and issues for the future Neurology 51 S53 1:CAS:528:DyaK1cXmtlyju70%3D 9744836
22. MJ Reeves S Arora JP Broderick, et al. 2005 Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry Stroke 36 1232 1240 10.1161/01.STR.0000165902.18021.5b 15890989 (Pubitemid 40798745)
23. W Hacke G Donnan C Fieschi, et al. 2004 Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 768 10.1016/S0140-6736(04)15692-4 15016487 (Pubitemid 38315166)
24. N Wahlgren N Ahmed A Davalos, et al. 2007 Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 275 282 10.1016/S0140-6736(07)60149-4 1:CAS:528:DC%2BD2sXpvV2gtw%3D%3D 17258667 (Pubitemid 46138121)
25. N Wahlgren N Ahmed A Davalos, et al. 2008 Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study Lancet 372 1303 1309 10.1016/S0140-6736(08)61339-2 1:CAS:528:DC%2BD1cXht1ejurbE 18790527
26. W Hacke M Kaste E Bluhmki, et al. 2008 Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 1317 1329 10.1056/NEJMoa0804656 1:CAS:528:DC%2BD1cXhtFGqu77E 18815396 This is a pivotal randomized controlled trial revealing statistically significant benefit when rt-PA is administered between 3 and 4.5 hours after symptom onset
27. GJ Del Zoppo JL Saver EC Jauch HP Adams Jr 2009 Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association Stroke 40 2945 2948 10.1161/STROKEAHA. 109.192535 19478221 This is a recent advisory statement from the AHA/ASA regarding expansion of the time window to 4.5 hours as a class 1 recommendation in selected patients
28. • Lyden P: Thrombolytic therapy for acute stroke-not a moment to lose. N Engl J Med 2008, 359:1393-1395. This editorial about the ECASS III trial reiterates that minimizing time to treatment is the ultimate goal, regardless of an expanded time window.